Hemin is an iron-containing porphyrin. Hemin strongly increased both expression and activity of HMOX after 4 and 12 h, respectively. Hemin treatment decreases cell proliferation to 62±5 %, 51±3 %, and 38±8 % in PA-TU-8902, BxPC-3 and MiaPaCa-2 cancer cells, respectively, with p<0.0001 for all comparisons.
In vivo, following the i.p. administration of Hemin (100 μmol/kg), the HO-1 level in the renal cortex begins to increase gradually. The HO-1 level reaches its peak 24 h after Hemin preconditioning. HO-1 is expressed mainly in the renal tubules.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO: ≥ 6 mg/mL (Need ultrasonic and warming)|
|Related Autophagy Products|
Autophinib is a novel potent autophagy inhibitor, inhibiting autophagy induced by starvation or Rapamycin with IC50 values of 90 and 40 nM, targeting the lipid kinase VPS34 with IC50 value of 19 nM in vitro.
AS1842856 is a cell-permeable Foxo1 inhibitor that blocks the transcription activity of Foxo1 with IC50 of 33 nM.
TBHQ is an aromatic organic compound, as a selective inducer of Nrf2 in a preclinical model of ICH.
SMER28 is an autophagy activator acting via an mTOR-independent mechanism. SMER28 prevents the accumulation of amyloid beta peptide.
SBC-115076 is an anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds, for the treatment and/or prevention of cardiovascular diseases. Target: PCSK9 in vivo: SBC-115076 lowers cholesterol levels in mice that are fed high fat diet.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.